The impact of diabetes and associated cardiometabolic risk factors on members: Strategies for optimizing outcomes

Chemical Compounds

• Antidiabetic Agent 100%
• Glycemic 91%
• Prescription Drug 59%
• Metabolic 47%
• Modification 32%
• Weight 18%
• Blood Pressure 14%
• Pharmaceutical 8%
• Lipid 8%

Medicine & Life Sciences

• Hypoglycemic Agents 49%
• Cardiovascular Diseases 32%
• Metabolic Syndrome 27%
• Prescription Drugs 26%
• Costs and Cost Analysis 23%
• Obesity 15%
• Cost-Benefit Analysis 12%
• Economics 11%
• Economic Models 10%
• Therapeutics 9%
• Incretins 9%
• Weights and Measures 9%
• Cost Control 9%
• Metabolome 8%
• Diabetes Complications 7%
• Smoking Cessation 7%
• Health 7%
• Consensus 7%
• Cluster Analysis 6%
• Overweight 6%
• Quality of Health Care 6%
• Weight Loss 6%
• Disease Progression 5%
• Maintenance 5%
• Lipids 4%
• Hypertension 4%
• Blood Pressure 4%
• Physicians 4%
• Pharmaceutical Preparations 3%
• Population 2%

Social Sciences

• chronic illness 80%
• cardiovascular disease 32%
• costs 16%
• medication 11%
• health plan 10%
• drug 8%
• comparative costs 6%
• management 6%
• clinical outcomes 5%
• clinical use 5%
• blood pressure 5%
• hypertension 5%
• economic model 4%
• smoking 4%
• pharmaceutical 3%
• economics 3%
• physician 3%
• cause 2%
• evaluation 1%
• resources 1%
• evidence 1%